For example, the CCL2/CCR2 pathway has been shown to be critical in the recruitment of TAMs to the GBM TME (Section 3.1.1); however, there are yet to be clinical trials evaluating targeting this pathway specifically in the context of GBM. This evidence concerns the gene CCR2 and glioblastoma.